Ibaflin
ibafloxacin
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Ibaflin has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 10/07/2013
Authorisation details
| Product details | |
|---|---|
| Name |
Ibaflin
|
| Agency product number |
EMEA/V/C/000052
|
| Active substance |
ibafloxacin
|
| International non-proprietary name (INN) or common name |
ibafloxacin
|
| Species |
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QJ01MA96
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Intervet International BV
|
| Revision |
7
|
| Date of issue of marketing authorisation valid throughout the European Union |
13/06/2000
|
| Contact address | |
Product information
26/05/2010 Ibaflin - EMEA/V/C/000052 - R/0019
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Antibacterials for systemic use
Therapeutic indication
Therapeutic indication
Dogs:
Ibaflin is indicated for the treatment of the following conditions in dogs:
- dermal infections (pyoderma - superficial and deep, wounds, abscesses) caused by susceptible strains of Staphylococci, Escherichia coli and Proteus mirabilis;
- acute, uncomplicated urinary-tract infections, caused by susceptible strains of Staphylococci, Proteus species, Enterobacter spp., E. coli and Klebsiella spp.;
- respiratory-tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and Klebsiella spp.
Ibaflin gel is indicated in dogs for the treatment of the following conditions:
- dermal infections (pyoderma - superficial and deep, wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp., E. coli and P. mirabilis.
Cats:
Ibaflin gel is indicated in cats for treatment of the following conditions:
- dermal infections (soft-tissue infections - wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp., E. coli, Proteus spp. and Pasteurella spp.;
- upper respiratory-tract infections caused by susceptible pathogens such as Staphylococcus spp., E. coli, Klebsiella spp. and Pasteurella spp.